Medicinal cannabis company Cronos Australia debuts on ASX
Published 08-NOV-2019 10:53 A.M.
|
4 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Medicinal cannabis company Cronos Australia (ASX:CAU) has successfully listed on the ASX.
Cronos Australia was established as a 50:50 joint venture with global cannabinoid company Cronos Group Inc. (TSE:CRON) and NewSouthern Capital.
The $3.5 billion capped Cronos Group was recently propelled by a big investment from Marlboro maker Altria (NASDAQ:MO).
Altria agreed to invest $1.8 billion for a 45% stake in Cronos Group, which would have given the Canadian cannabis player further confidence to acquire CBD brand, Lord Jones.
Cronos Group announced the Lord Jones acquisition in August.
Stifel analyst Andrew Carter upgraded Cronos Group stock from hold to buy in a research note released late in October. He did, however, trim his price target to CAD14.0 from CAD16.50.
"We believe Cronos will showcase an enhanced revenue growth profile leveraging the distribution capabilities of Altria to build its US CBD business and demonstrate breakthrough product potential in the Canadian vapor segment," Carter said.
Interestingly, CRON’s net income improved from $2 million in 2017 to $498 million in the trailing twelve month (TTM) period. However, in that same period, after-tax operating profit (NOPAT), fell from -$7 million to -$33 million.
Yet, Cronos Group has been riding a wave of positive investor sentiment in the overall legal cannabis market and this could have an impact on Cronos Australia.
Cronos Group holds approximately 31% of the issued capital of Cronos Australia.
What does Cronos Australia do?
Cronos Australia aims to become a leading health and wellness company in the Asia Pacific region through the distribution of premium cannabis products.
"The ASX listing is a significant milestone in the life of Cronos Australia, and we look forward to delivering on our vision of being a leading health and wellness company in the Asia-Pacific Region through a portfolio of successful, premium cannabinoid brands and products," Shane Tanner, Chairman of Cronos Australia noted.
The Australian medicinal cannabis company listed on the ASX following a successful A$20 million initial public offering (IPO) from institutional and sophisticated investors in October.
Cronos Australia offered 40 million shares at A$0.50 each for an indicative market capitalisation at the close of the offer of A$64.4 million.
The company is currently capped at $43.7 million and is trading at $0.340.
Early revenues will be generated from the import and distribution of PEACE NATURALTM medicinal cannabis products which are currently sold in Canada and Germany.
Having ready-made products, will enable Cronos Australia to develop its own branded products and also has access to certain elements of Cronos Group's intellectual property – subject to the terms of an IP license agreement between Cronos Group and Cronos Australia.
Cronos Australia is pursuing an asset-light business model under which the cultivation of medicinal cannabis and the manufacturing of medicinal cannabis products is expected to be outsourced to other companies both domestically and overseas.
Cronos Australia Chief Executive Officer, Rodney Cocks, said, "Cronos Australia is excited to join this fast-emerging sector as Australia's newest listed medical cannabis company. Our asset-light business model, backing of Cronos Group and Asia-Pacific focus give the company a unique proposition in our market.
"We look forward to providing future updates to the market as the funds raised are deployed to accelerate the development and commercialisation of our portfolio of medicinal cannabis products."
Cronos Australia was formed to accelerate growth and capture opportunities relating to the emerging cannabis industry domestically and internationally.
Whilst the Australian market is still in its infancy, the requirement for medicinal cannabis is expected to grow as the complexities of legislation and regulation untangle and markets open.
Having Cronos Group in its corner should give the newly listed Cronos Australia, a solid foundation in the burgeoning Australian market, as well a foothold in already developing international markets.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
